IFNG and myeloid sarcoma: They suppress the T-Helper 1 (TH1) response, thereby reducing the release of interferon gamma and tumor necrosis factor alpha associated with MS episodes, in addition to increasing the TH2 response related to the circulation of interleukins 4 and 10, involved in maternal immune tolerance toward the presence of the fetus, thereby reducing the intensity and number of episodes of MS during pregnancy (Fragoso et al., 2018).